

### **AMENDMENTS TO THE CLAIMS**

The listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

Claims 1-20 (Canceled)

21. (currently amended) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence having 80% 98% sequence homology or greater to SEQ ID NO: 4.

22. (previously presented) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises SEQ ID NO: 4.

23. (previously presented) An isolated antibody or antibody fragment according to claim 21, wherein said protein has a sequence homology equal to or greater than 80% to SEQ ID NO: 2 or 3.

24. (previously presented) An isolated antibody or antibody fragment according to claim 22, wherein said protein has a sequence homology equal to or greater than 80% to SEQ ID NO: 2 or 3.

25. (previously presented) An antibody or antibody fragment according to claim 21 wherein said peptide has an amino acid sequence comprising at least 10 contiguous amino acid residues of SEQ ID NO: 2.

26. (previously presented) The antibody according to claim 21 which is a monoclonal antibody or fragment thereof.

27. (previously presented) The antibody according to claim 22 which is a monoclonal antibody or fragment thereof.

28. (previously presented) The antibody according to claim 23 which is a monoclonal antibody or fragment thereof.

29. (previously presented) The antibody according to claim 24 which is a monoclonal antibody or fragment thereof.

30. (previously presented) A recombinant cell expressing the antibody according to any one of claims 21-29.

31. (currently amended) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence encoded for by a nucleic acid molecule that binds under stringent conditions to the nucleotide sequence from position 2180-2608 of SEQ ID NO: 1 wherein said stringent conditions are those in which the salt concentration is less than 1.0 M Na ion at pH 7.0 to 8.3 and the temperature is at least 30°C for probes 10 to 50 nucleotides in length and at least 60°C for probes greater than 50 nucleotides in length.

32. (currently amended) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence encoded for by a nucleic acid molecule that binds under stringent conditions to the nucleotide sequence from position 797-2824 of SEQ ID NO: 1 wherein said stringent conditions are those in which the salt concentration is less than 1.0 M Na ion at pH 7.0 to 8.3 and the temperature is at least 30°C for probes 10 to 50 nucleotides in length and at least 60°C for probes greater than 50 nucleotides in length.

33. (withdrawn) A method for treating an angiogenesis related disease or disorder comprising administering an effective amount of an antibody of any one of claims 21-29 or 31-32 to a patient in need thereof.